Direkt zum Inhalt
Merck
  • Direct Contraction Force Measurements of Engineered Cardiac Tissue Constructs With Inotropic Drug Exposure.

Direct Contraction Force Measurements of Engineered Cardiac Tissue Constructs With Inotropic Drug Exposure.

Frontiers in pharmacology (2022-05-21)
Maria Koivisto, Milad Mosallaei, Tarja Toimela, Sampo Tuukkanen, Tuula Heinonen
ZUSAMMENFASSUNG

Contractility is one of the most crucial functions of the heart because it is directly related to the maintenance of blood perfusion throughout the body. Both increase and decrease in contractility may cause fatal consequences. Therefore, drug discovery would benefit greatly from reliable testing of candidate molecule effects on contractility capacity. In this study, we further developed a dual-axis piezoelectric force sensor together with our human cell-based vascularized cardiac tissue constructs for cardiac contraction force measurements. The capability to detect drug-induced inotropic effects was tested with a set of known positive and negative inotropic compounds of isoprenaline, milrinone, omecamtiv mecarbil, propranolol, or verapamil in different concentrations. Both positive and negative inotropic effects were measurable, showing that our cardiac contraction force measurement system including a piezoelectric cantilever sensor and a human cell-based cardiac tissue constructs has the potential to be used for testing of inotropic drug effects.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Fibrinogen aus Humanplasma, 50-70% protein (≥80% of protein is clottable)
Sigma-Aldrich
Aprotinin aus Rinderlunge, lyophilized powder, 3-8 TIU/mg solid
Sigma-Aldrich
(±)-Propranolol -hydrochlorid, ≥99% (TLC), powder
Sigma-Aldrich
Thrombin aus Humanplasma, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)